5月22日，ImmunityBio盘中下跌5.23%，报7.335美元/股，成交额2022.58万美元。此前该股已于5月21日下跌7.89%，本轮回调延续获利了结态势。
消息面上，公司近期密集释放多项利好：与日本BCG实验室签署独家美国协议引进Tokyo-172卡介苗、获得五项覆盖ANKTIVA联合BCG治疗癌症的美国专利（有效期至少至2035年），以及在AUA年会上公布Nai+BCG相较Nadofaragene与TAR-200的积极完全缓解率数据。尽管基本面催化剂密集落地，但利好集中兑现后市场抛压显现，成交额较前一交易日明显缩量，显示卖盘力度有所减弱但多头承接意愿仍偏弱。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.